{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:46Z","timestamp":1791213286285,"version":"4.1.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Neurosciences"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.tins.2019.05.010","type":"journal-article","created":{"date-parts":[[2019,7,6]],"date-time":"2019-07-06T08:08:09Z","timestamp":1562400489000},"page":"631-643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?"],"prefix":"10.1016","volume":"42","author":[{"given":"Tamar","family":"Farfel-Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahid","family":"Tayebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tins.2019.05.010_bb0005","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1073\/pnas.95.11.6469","article-title":"Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson\u2019s disease and dementia with lewy bodies","volume":"95","author":"Spillantini","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0010","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneurol.2013.132","article-title":"Advances in the genetics of Parkinson disease","volume":"9","author":"Trinh","year":"2013","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0015","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1474-4422(12)70190-4","article-title":"The link between the GBA gene and parkinsonism","volume":"11","author":"Sidransky","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0020","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3109\/10409239009090616","article-title":"Acid beta-glucosidase: enzymology and molecular biology of Gaucher disease","volume":"25","author":"Grabowski","year":"1990","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"10.1016\/j.tins.2019.05.010_bb0025","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1136\/jmg.2004.028019","article-title":"Divergent phenotypes in Gaucher disease implicate the role of modifiers","volume":"42","author":"Goker-Alpan","year":"2005","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0030","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","article-title":"The complicated relationship between Gaucher disease and parkinsonism: insights from a rare disease","volume":"93","author":"Aflaki","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.tins.2019.05.010_bb0035","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","article-title":"The incidence of parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry","volume":"46","author":"Rosenbloom","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.tins.2019.05.010_bb0040","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease","volume":"361","author":"Sidransky","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tins.2019.05.010_bb0045","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1212\/NXG.0000000000000104","article-title":"GBA p.T369M substitution in Parkinson disease: polymorphism or association? A meta-analysis","volume":"2","author":"Mallett","year":"2016","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0050","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1001\/jamaneurol.2016.2245","article-title":"Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease","volume":"73","author":"Davis","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1212\/WNL.0000000000001315","article-title":"Differential effects of severe vs mild GBA mutations on Parkinson disease","volume":"84","author":"Gan-Or","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.tins.2019.05.010_bb0060","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ana.24777","article-title":"Survival and dementia in GBA-associated Parkinson\u2019s disease: the mutation matters","volume":"80","author":"Cilia","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/mds.27583","article-title":"Glucocerebrosidase mutations and synucleinopathies: toward a model of precision medicine","volume":"34","author":"Blandini","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tins.2019.05.010_bb0070","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/jamaneurol.2014.313","article-title":"Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes","volume":"71","author":"Alcalay","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0075","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.parkreldis.2016.12.014","article-title":"A \u201cdose\u201d effect of mutations in the GBA gene on Parkinson\u2019s disease phenotype","volume":"36","author":"Thaler","year":"2017","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.tins.2019.05.010_bb0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/jamaneurol.2013.1925","article-title":"A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies","volume":"70","author":"Nalls","year":"2013","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0085","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1111\/febs.14393","article-title":"The role of glucocerebrosidase in Parkinson disease pathogenesis","volume":"285","author":"Gegg","year":"2018","journal-title":"FEBS J."},{"key":"10.1016\/j.tins.2019.05.010_bb0090","doi-asserted-by":"crossref","first-page":"28080","DOI":"10.1074\/jbc.M111.237859","article-title":"Alpha-synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases","volume":"286","author":"Yap","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tins.2019.05.010_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","article-title":"Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies","volume":"146","author":"Mazzulli","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tins.2019.05.010_bb0100","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes alpha-synuclein pathology in mutant GBA-associated Parkinson\u2019s disease","volume":"37","author":"Taguchi","year":"2017","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2019.05.010_bb0105","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.1616152114","article-title":"Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models","volume":"114","author":"Sardi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0110","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/mds.26278","article-title":"No evidence for substrate accumulation in Parkinson brains with GBA mutations","volume":"30","author":"Gegg","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tins.2019.05.010_bb0115","first-page":"2712","article-title":"The contribution of mutant GBA to the development of Parkinson disease in Drosophila","volume":"25","author":"Maor","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0120","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/hmg\/ddz005","article-title":"The effect of mutant GBA1 on accumulation and aggregation of alpha-synuclein","volume":"28","author":"Maor","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0125","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ana.23614","article-title":"Glucocerebrosidase deficiency in substantia nigra of Parkinson disease brains","volume":"72","author":"Gegg","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0130","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/brain\/awt367","article-title":"Reduced glucocerebrosidase is associated with increased \u03b1-synuclein in sporadic Parkinson\u2019s disease","volume":"137","author":"Murphy","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.tins.2019.05.010_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","article-title":"Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies","volume":"10","author":"Chiasserini","year":"2015","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tins.2019.05.010_bb0140","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/14789450.2016.1174583","article-title":"Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease","volume":"13","author":"Jung","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.tins.2019.05.010_bb0145","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.stemcr.2017.01.011","article-title":"A human neural crest stem cell-derived dopaminergic neuronal model recapitulates biochemical abnormalities in GBA1 mutation carriers","volume":"8","author":"Yang","year":"2017","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.tins.2019.05.010_bb0150","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-014-0294-x","article-title":"A GCase chaperone improves motor function in a mouse model of synucleinopathy","volume":"11","author":"Richter","year":"2014","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.tins.2019.05.010_bb0155","doi-asserted-by":"crossref","DOI":"10.1002\/syn.21967","article-title":"Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate","volume":"71","author":"Migdalska-Richards","year":"2017","journal-title":"Synapse"},{"key":"10.1016\/j.tins.2019.05.010_bb0160","doi-asserted-by":"crossref","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","article-title":"A new glucocerebrosidase chaperone reduces alpha-synuclein and glycolipid levels in iPSC-derived dopaminergic neurons from patients with Gaucher disease and parkinsonism","volume":"36","author":"Aflaki","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2019.05.010_bb0165","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of beta-glucocerebrosidase reduces pathological alpha-synuclein and restores lysosomal function in Parkinson\u2019s patient midbrain neurons","volume":"36","author":"Mazzulli","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tins.2019.05.010_bb0170","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.neuron.2016.08.013","article-title":"Genetic background limits generalizability of genotype-phenotype relationships","volume":"91","author":"Sittig","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.tins.2019.05.010_bb0175","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/bs.ctdb.2016.07.005","article-title":"Mechanisms of Parkinson\u2019s disease: lessons from Drosophila","volume":"121","author":"Hewitt","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.tins.2019.05.010_bb0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00702-017-1772-1","article-title":"Parkinson\u2019s disease pathogenesis from the viewpoint of small fish models","volume":"125","author":"Matsui","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.tins.2019.05.010_bb0185","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.008185","article-title":"Animal models for Gaucher disease research","volume":"4","author":"Farfel-Becker","year":"2011","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.tins.2019.05.010_bb0190","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fnana.2014.00155","article-title":"Parkinson\u2019s disease: animal models and dopaminergic cell vulnerability","volume":"8","author":"Blesa","year":"2014","journal-title":"Front. Neuroanat."},{"key":"10.1016\/j.tins.2019.05.010_bb0195","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.tins.2019.05.010_bb0200","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.95.5.2503","article-title":"Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymgme.2013.12.003","article-title":"Neuroinflammation and alpha-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction","volume":"111","author":"Ginns","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0210","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1172\/JCI0214530","article-title":"Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage","volume":"109","author":"Mizukami","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.tins.2019.05.010_bb0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/15548627.2018.1509818","article-title":"Mitochondrial dysfunction and mitophagy defect triggered by heterozygous GBA mutations","volume":"15","author":"Li","year":"2019","journal-title":"Autophagy"},{"key":"10.1016\/j.tins.2019.05.010_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-017-0233-5","article-title":"Alpha-synuclein accumulation and GBA deficiency due to L444P GBA mutation contributes to MPTP-induced parkinsonism","volume":"13","author":"Yun","year":"2018","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.tins.2019.05.010_bb0225","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/mds.25462","article-title":"Lysosomal impairment in Parkinson\u2019s disease","volume":"28","author":"Dehay","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.tins.2019.05.010_bb0230","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.tibs.2015.02.003","article-title":"Mitochondrial dysfunction and mitophagy in Parkinson\u2019s: from familial to sporadic disease","volume":"40","author":"Ryan","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.tins.2019.05.010_bb0235","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1093\/brain\/awu291","article-title":"Augmentation of phenotype in a transgenic Parkinson mouse heterozygous for a Gaucher mutation","volume":"137","author":"Fishbein","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.tins.2019.05.010_bb0240","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1093\/brain\/awx221","article-title":"The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice","volume":"140","author":"Migdalska-Richards","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.tins.2019.05.010_bb0245","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cell.2005.09.028","article-title":"Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration","volume":"123","author":"Chandra","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.tins.2019.05.010_bb0250","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnmol.2018.00043","article-title":"Integrated genetic analysis of racial differences of common GBA variants in Parkinson\u2019s disease: a meta-analysis","volume":"11","author":"Zhang","year":"2018","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.tins.2019.05.010_bb0255","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(95)91688-1","article-title":"Gaucher\u2019s disease variant characterised by progressive calcification of heart valves and unique genotype","volume":"346","author":"Abrahamov","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.tins.2019.05.010_bb0260","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0002-9440(10)63566-3","article-title":"Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease","volume":"163","author":"Xu","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.tins.2019.05.010_bb0265","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2008.01.013","article-title":"Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels","volume":"94","author":"Xu","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0270","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40478-018-0538-9","article-title":"D409H GBA1 mutation accelerates the progression of pathology in A53T alpha-synuclein transgenic mouse model","volume":"6","author":"Kim","year":"2018","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.tins.2019.05.010_bb0275","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ymgme.2010.12.014","article-title":"Accumulation and distribution of alpha-synuclein and ubiquitin in the CNS of Gaucher disease mouse models","volume":"102","author":"Xu","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0280","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1073\/pnas.132197599","article-title":"Human alpha-synuclein-harboring familial Parkinson\u2019s disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice","volume":"99","author":"Lee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0285","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1093\/nar\/17.19.7707","article-title":"Comparison of RNase A, a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene","volume":"17","author":"Theophilus","year":"1989","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.tins.2019.05.010_bb0290","doi-asserted-by":"crossref","first-page":"12101","DOI":"10.1073\/pnas.1108197108","article-title":"CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy","volume":"108","author":"Sardi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0295","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1073\/pnas.1220464110","article-title":"Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies","volume":"110","author":"Sardi","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0300","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/ana.22400","article-title":"Acid beta-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter alpha-synuclein processing","volume":"69","author":"Cullen","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tins.2019.05.010_bb0305","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0896-6273(02)00682-7","article-title":"Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein","volume":"34","author":"Giasson","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.tins.2019.05.010_bb0310","first-page":"1696","article-title":"Modulation of beta-glucocerebrosidase increases alpha-synuclein secretion and exosome release in mouse models of Parkinson\u2019s disease","volume":"27","author":"Papadopoulos","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0315","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ymgme.2014.11.008","article-title":"The clinical management of Type 2 Gaucher disease","volume":"114","author":"Weiss","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0320","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/357407a0","article-title":"Animal model of Gaucher\u2019s disease from targeted disruption of the mouse glucocerebrosidase gene","volume":"357","author":"Tybulewicz","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.tins.2019.05.010_bb0325","doi-asserted-by":"crossref","first-page":"17483","DOI":"10.1073\/pnas.0708086104","article-title":"Murine models of acute neuronopathic Gaucher disease","volume":"104","author":"Enquist","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0330","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/s41591-018-0106-7","article-title":"Fetal gene therapy for neurodegenerative disease of infants","volume":"24","author":"Massaro","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.tins.2019.05.010_bb0335","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/hmg\/ddr019","article-title":"Spatial and temporal correlation between neuron loss and neuroinflammation in a mouse model of neuronopathic Gaucher disease","volume":"20","author":"Farfel-Becker","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0340","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cmet.2013.04.014","article-title":"Mitochondria and quality control defects in a mouse model of Gaucher disease -- links to Parkinson\u2019s disease","volume":"17","author":"Osellame","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0345","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/hmg\/ddt468","article-title":"Neuronal accumulation of glucosylceramide in a mouse model of neuronopathic Gaucher disease leads to neurodegeneration","volume":"23","author":"Farfel-Becker","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0350","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/hmg\/ddx120","article-title":"Glucocerebrosidase deficiency in dopaminergic neurons induces microglial activation without neurodegeneration","volume":"26","author":"Soria","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162367","article-title":"Progression of behavioral and CNS deficits in a viable murine model of chronic neuronopathic Gaucher disease","volume":"11","author":"Dai","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tins.2019.05.010_bb0360","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/hmg\/ddz030","article-title":"GBA haploinsufficiency accelerates alpha synuclein pathology with altered lipid metabolism in a prodromal model of Parkinson\u2019s disease","volume":"28","author":"Ikuno","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0365","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2017.11.001","article-title":"Glucocerebrosidase haploinsufficiency in A53T alpha-synuclein mice impacts disease onset and course","volume":"122","author":"Tayebi","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0370","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neures.2012.03.010","article-title":"Alpha-synuclein BAC transgenic mice as a model for Parkinson\u2019s disease manifested decreased anxiety-like behavior and hyperlocomotion","volume":"73","author":"Yamakado","year":"2012","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.tins.2019.05.010_bb0375","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-291X(75)90286-7","article-title":"The Gaucher mouse","volume":"67","author":"Kanfer","year":"1975","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.tins.2019.05.010_bb0380","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/path.4751","article-title":"Delineating pathological pathways in a chemically induced mouse model of Gaucher disease","volume":"239","author":"Vardi","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.tins.2019.05.010_bb0385","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.celrep.2016.07.085","article-title":"Identification of modifier genes in a mouse model of Gaucher disease","volume":"16","author":"Klein","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tins.2019.05.010_bb0390","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","article-title":"Alpha-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism","volume":"30","author":"Manning-Bog","year":"2009","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.tins.2019.05.010_bb0395","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1089\/ars.2015.6307","article-title":"Sustained systemic glucocerebrosidase inhibition induces brain alpha-synuclein aggregation, microglia and complement C1q activation in mice","volume":"23","author":"Rocha","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.tins.2019.05.010_bb0400","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.nbd.2018.12.001","article-title":"Development and biochemical characterization of a mouse model of Parkinson\u2019s disease bearing defective glucocerebrosidase activity","volume":"124","author":"Mus","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tins.2019.05.010_bb0405","first-page":"2645","article-title":"Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson\u2019s disease","volume":"25","author":"Rockenstein","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0410","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/BCJ20180708","article-title":"Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells","volume":"476","author":"Qi","year":"2019","journal-title":"Biochem. J."},{"key":"10.1016\/j.tins.2019.05.010_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2014.08.022","article-title":"The protective role of prosaposin and its receptors in the nervous system","volume":"1585","author":"Meyer","year":"2014","journal-title":"Brain Res."},{"key":"10.1016\/j.tins.2019.05.010_bb0420","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/hmg\/5.6.711","article-title":"Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids","volume":"5","author":"Fujita","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.tins.2019.05.010_bb0425","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1096-7192(02)00114-2","article-title":"Prosaposin: threshold rescue and analysis of the \u201cneuritogenic\u201d region in transgenic mice","volume":"76","author":"Sun","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.tins.2019.05.010_bb0430","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms11992","article-title":"Prosaposin is a regulator of progranulin levels and oligomerization","volume":"7","author":"Nicholson","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tins.2019.05.010_bb0435","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.neuroscience.2013.01.007","article-title":"Attenuation of MPTP\/MPP(+) toxicity in vivo and in vitro by an 18-mer peptide derived from prosaposin","volume":"236","author":"Gao","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.tins.2019.05.010_bb0440","doi-asserted-by":"crossref","first-page":"15573","DOI":"10.1073\/pnas.1405700111","article-title":"LIMP-2 expression is critical for beta-glucocerebrosidase activity and alpha-synuclein clearance","volume":"111","author":"Rothaug","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tins.2019.05.010_bb0445","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/humu.21566","article-title":"A mutation in SCARB2 is a modifier in Gaucher disease","volume":"32","author":"Velayati","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.tins.2019.05.010_bb0450","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2007.10.018","article-title":"LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase","volume":"131","author":"Reczek","year":"2007","journal-title":"Cell"}],"container-title":["Trends in Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016622361930092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016622361930092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:15:39Z","timestamp":1759061739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016622361930092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S016622361930092X"],"URL":"https:\/\/doi.org\/10.1016\/j.tins.2019.05.010","relation":{},"ISSN":["0166-2236"],"issn-type":[{"value":"0166-2236","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can GBA1-Associated Parkinson Disease Be Modeled in the Mouse?","name":"articletitle","label":"Article Title"},{"value":"Trends in Neurosciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tins.2019.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}